Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
NCT07121777 · Autoimmune Diseases
RecruitingThis is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with an Anti- CD19/BCMA CAR gene vector injection
PhaseNA
TypeInterventional
Age18 Years
WhereHefei, Anhui, China
SponsorAnhui Provincial Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Systemic Lupus Erythematosus in Gullah Health
RecruitingSystemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.
Phase—
TypeObservational
Age2 Years
WhereCharleston, South Carolina, United States
SponsorMedical University of South Carolina
▾Tap for detailsClick for full details — eligibility, all locations, contacts Trial of Belimumab in Early Lupus
RecruitingThis two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years. Subjects will be randomized to receive belimumab or placebo during the first year. During the second year, subjects who were randomized to belimumab will be rerandomized to continue to receive belimumab or to receive placebo. The study will look at clinical effects as well as effects on the immune system.
PhasePhase 4
TypeInterventional
Age18 Years
WhereManhasset, New York, United States
SponsorNorthwell Health
▾Tap for detailsClick for full details — eligibility, all locations, contacts Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
NCT05567198 ·
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
RecruitingBackground: Systemic lupus erythematosus (SLE) is a disease that affects females nine times more often than males. People with SLE are often treated with cyclophosphamide (CYC). But CYC can damage a woman s ovaries; it may cause infertility. A drug called GnRHa is sometimes given to protect the ovaries during CYC therapy. But no one really knows how effective GnRHa treatment is. This natural history survey will compare women who received GnRHa during CYC therapy with those who did not. Objective: To find out whether GnRHa can help protect women s ovaries during CYC. Eligibility: Women under age 40 years starting CYC treatment with or without GnRHa. Design: This study will do 2 things: It will conduct patient surveys. It will collect data from medical records. Participants will complete a one-time survey. They will answer questions about their menstrual cycle. They will be asked about their history of pregnancy or infertility. Participants can take the survey in 4 ways: On paper, sent through the mail. Online, in a secure web page managed by the NIH. By phone. In person, during a routine visit to the NIH clinic. The survey will take about 30 minutes. Participants medical records will be reviewed. Researchers will look for data about the participants SLE disease. This may include their symptoms and the results of their blood tests. It may also include the details of prior treatments. Researchers will also collect data about participants reproductive history. This may include their personal or family history of infertility. It may include any fertility treatments and any sexually transmitted infections.
Phase—
TypeObservational
Age18 Years – 120 Years
WhereBethesda, Maryland, United States
SponsorNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
▾Tap for detailsClick for full details — eligibility, all locations, contacts Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment
RecruitingThe goal of this observational study is to investigate different phenotypes among patients with SLE and to compare with matched general population controls. The main questions we aim to answer are: A To investigate if subgroups of patients with systemic lupus erythematosus (SLE) defined by autoantibodies, genetic predisposition or biomarkers, rather than the present diagnostic entities account for the high risk of premature vascular disease. B To perform in depth studies of selected patient groups to shed light on the autoimmune mechanisms behind antiphospholipid (aPL) antibodies and nephritis and their association to vascular disease in SLE and APS Participants will be investigated in person by a nurse and a rheumatologist. Data on previous and present disease characteristics, anthropometric measurements and health related quality of life (according to selfreported questionnaires) will be entered into a data base. Blood samples (plasma serum and DNA), urine and saliva is stored in a corresponding biobank. Researchers will compare identified subgroups of SLE patients to each other and to matched population controls.
Phase—
TypeObservational
Age18 Years – 100 Years
WhereStockholm, Sweden
SponsorRegion Stockholm
▾Tap for detailsClick for full details — eligibility, all locations, contacts Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
RecruitingThis investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 65 Years
WhereNanjing, Jiangsu, China
SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
▾Tap for detailsClick for full details — eligibility, all locations, contacts Wellness & Workforce Solution for Lupus/Lupus Nephritis
RecruitingThe investigators will test the hypothesis that culturally congruent coaching delivered via a technology application (Health360x) will improve the persistent disparities observed among women of color with lupus or lupus nephritis by addressing underlying psychosocial barriers to behavioral change.
PhaseNA
TypeInterventional
Age18 Years
WhereAtlanta, Georgia, United States
SponsorMorehouse School of Medicine
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
RecruitingThis study is a randomized, controlled, phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with systemic lupus erythematosus.
PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereShanghai, Shanghai Municipality, China
SponsorSichuan Baili Pharmaceutical Co., Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
NCT06497387 ·
Lupus Nephritis, IgG4-related Disease
RecruitingA Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years
WhereWuhan, Hubei, China
SponsorTongji Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382 · Membranous Nephropathy,
Lupus Nephritis (LN) RecruitingThe primary objectives of this clinical trial is to evaluate the safety and tolerability of HLX79 in combination with HLX01 versus placebo in combination with HLX01 in the treatment of glomerulonephritis. The secondary objective are to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HLX79 and HLX01, the clinical efficacy, the dynamic changes of biomarkers of HLX79 in combination with HLX01 in the treatment of glomerulonephritis. The subjects will receive different doses of HLX79 (10, 20, or 30 mg/kg) or placebo, all in combination with HLX01. After the end of the first treatment period, subjects will enter a 20-week follow-up period and then undergo pre-second treatment period assessments. If the investigator determines that the subject does not require the second treatment period, the subject will continue in follow-up until completing the total 48-week follow-up period.
PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereBeijing, China + 16 more
SponsorShanghai Henlius Biotech
▾Tap for detailsClick for full details — eligibility, all locations, contacts MTS109 in Patients With Refractory Autoimmune Diseases
NCT07526350 ·
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc)
RecruitingThis is the first-in-human trial of MTS109 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS109 in moderate to severe autoimmune diseases.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 65 Years
WhereShanghai, Shanghai Municipality, China
SponsorShanghai Changzheng Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT07193810 ·
SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis
RecruitingThis study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or refractory autoimmune diseases.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 65 Years
WhereDeyang, Sichuan, China
SponsorCytoCares Inc
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
RecruitingThis is an open-label, multi-ascending dose (MAD) phase 1 study, with dose expansion at selected doses, in adult patients with select autoimmune rheumatic diseases including systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The purpose of the study is to identify possible optimal dose(s) by assessing the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary clinical response of SAR448501/DR-0201. The study duration per participant will be a minimum of approximately 13 months, including a screening period of up to 28 days, a treatment period of 71 days, and a follow-up period of 42 weeks. If necessary, participants will continue to have visits after End of Study (EOS) every 4 weeks until peripheral blood B cells return to at least 80% of either the lower limit of normal (LLN) or the participant's baseline value.
PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereMelbourne, Victoria, Australia + 7 more
SponsorSanofi
▾Tap for detailsClick for full details — eligibility, all locations, contacts Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
RecruitingLupus Low Disease Activity State (LLDAS) study is an international, multi-centre prospective study, developed by the Asia Pacific Lupus Collaboration (APLC) to investigate whether the attainment of LLDAS is associated with improved outcomes in patients with Systemic Lupus Erythematosus (SLE). SLE, or lupus, is the archetypal multisystem autoimmune disease, with an estimated incidence of 5-50 cases per 100,000 people. Patients with SLE, usually young women, suffer a marked loss of life expectancy, and severe morbidity, due to a heterogeneous range of clinical manifestations caused by autoimmune-mediated inflammation of multiple organs. The most severe manifestations of SLE are the accrual of irreversible organ damage, especially renal and central nervous system (CNS) involvement. As there is no effective targeted monotherapy for SLE, patients also suffer severe toxicity from the use of glucocorticoids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and inexorably accrue permanent organ damage over time. The diversity of clinical features of active SLE has made quantification of disease activity problematic. Although there are a number of published systems in use to measure SLE disease activity, there are widely acknowledged problems with these instruments. Published definitions of remission are so stringent that they are met by less than 5% of patients. This lead to the realisation that rather than lupus remission, a lupus low disease activity state target may be more feasible, and that patients with low disease activity are more homogeneous than patients with active disease. Thus, the development of a definition of lupus low disease activity, which is feasible and has face validity, escapes the complexity of attempts to quantify heterogeneous states of active disease. In this study, the investigators will prospectively collect longitudinal data on consecutive SLE patients at each centre to evaluate the LLDAS definition. Protection from organ damage accrual as the primary endpoint.
Phase—
TypeObservational
Age18 Years
WhereAdelaide, South Australia, Australia + 19 more
SponsorMonash University
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
RecruitingThis study is a multicenter Phase Ib/II clinical trial aimed at evaluating the safety, tolerability and efficacy of SCTB35 in patients with systemic lupus erythematosus (SLE).
PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 75 Years
WhereBeijing, China + 13 more
SponsorSinocelltech Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
RecruitingSystemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by heterogeneous clinical manifestations ranging from mild cutaneous involvement to severe multi-organ damage. While its pathogenesis involves complex cytokine dysregulation, emerging evidence implicates IL-17 as a potential contributor. Elevated serum IL-17 levels have been observed in SLE patients compared to healthy controls, with heightened expression detected in renal and cutaneous lesions. Ustekinumab, a monoclonal antibody targeting IL-23/IL-12 that indirectly modulates IL-17 signaling, demonstrated superior efficacy and safety to placebo in an SLE clinical trial, particularly in glucocorticoid dose reduction. Notably, no clinical trials have directly evaluated IL-17-targeted therapies for SLE, though case reports suggest secukinumab (an anti-IL-17A agent) may improve cutaneous manifestations in psoriasis-SLE overlap patients. Vunakizumab, a humanized anti-IL-17A monoclonal antibody (IgG1/κ) with a unique epitope-binding profile, selectively inhibits IL-17A-mediated inflammatory signaling. Its established safety profile and infrequent dosing regimen in IL-17-mediated diseases (e.g., psoriasis, psoriatic arthritis) warrant investigation in SLE. The investigators aim to provide new treatment options for SLE patients
PhasePhase 1
TypeInterventional
Age18 Years – 65 Years
WhereBeijing, Beijing Municipality, China
SponsorChinese SLE Treatment And Research Group
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
RecruitingThe purpose of this study is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while on background standard of care (SoC) therapy.
PhasePhase 2
TypeInterventional
Age5 Years – 17 Years
WhereNedlands, Australia + 38 more
SponsorAstraZeneca
▾Tap for detailsClick for full details — eligibility, all locations, contacts Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
NCT05858684 · CAR-T Cell Therapy
RecruitingThis is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.
PhaseEARLY_Phase 1
TypeInterventional
Age18 Years – 70 Years
WhereShanghai, Shanghai Municipality, China
SponsorRenJi Hospital
▾Tap for detailsClick for full details — eligibility, all locations, contacts Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
NCT07249060 · Immune-Related Adverse Events,
Lupus Erythematosus, Systemic, Sjogren Syndrome
RecruitingThis study aims to identify a way to predict the side effects that some people with cancer experience when receiving immunotherapy. These side effects, known as immune-related adverse events (irAEs), occur when the immune system mistakenly attacks healthy tissues, like certain autoimmune diseases. At present, clinicians lack reliable tests to determine who is most likely to develop these reactions. The goal of this study is to determine whether substances in the blood called interferons (IFNs) could serve as early warning markers. The study will include 300 people with cancer who are about to begin immunotherapy. To provide a meaningful comparison, the investigators will also enroll 40 individuals with autoimmune diseases such as lupus. Understanding how IFN levels differ between these groups may help clarify whether IFN patterns in cancer patients resemble those seen in autoimmune disease. Participants in both groups will be asked to provide small blood samples at predefined time points during their clinical care or treatment. Researchers will measure the levels of different IFN types in all samples to compare IFN levels between cancer patients and individuals with autoimmune diseases, and within the cancer group between patients who develop irAEs and those who do not. The long-term aim of the study is to develop a simple test that can help clinicians identify patients at higher risk of irAEs. Immune-related adverse events (irAEs) are a frequent complication in cancer patients treated with immune checkpoint inhibitors (ICIs), and they often resemble or exacerbate preexisting autoimmune diseases. Despite extensive research in the field, no validated predictive biomarkers of irAEs currently exist. Emerging evidence suggests that the IFN signature -long implicated in the pathogenesis of several systemic autoimmune diseases (SADs)- may also be upregulated in patients who develop ICI-induced irAEs, likely with substantial overlap among different IFN subtypes. Given these clinical and molecular similarities with SADs, it is plausible that IFN levels in peripheral blood carry predictive value for irAE risk, although the dominant IFN types in ICI-related toxicity remain unknown. The INTER-AUTENTIC project aims to determine whether baseline IFN levels and their dynamic changes, measured in peripheral blood using a dedicated panel, can predict the onset of irAEs in cancer patients receiving ICIs. Supported by the Medical Oncology departments of six university hospitals in Northern Spain, this multicenter, observational, prospective cohort study has been underway since 2021. Biobank samples have been collected from ICI-treated patients before treatment initiation, at protocol-defined time points, and at the moment of irAE diagnosis (ICI cohort). The study seeks to identify the IFN subtypes with the most pronounced differential expression between patients with and without irAEs, and to evaluate whether IFN levels enhance the predictive performance of a model incorporating other clinical variables potentially associated with immune-mediated toxicity. A sample size of 300 cancer patients has been estimated for this analysis. In addition, a second prospective cohort of 40 non-cancer patients with systemic lupus erythematosus, primary Sjögren's syndrome, systemic sclerosis, and/or idiopathic inflammatory myopathy (SAD cohort) will be included. Since IFNs play a well-established pathogenic role in these conditions, this cohort will allow characterization of the IFN signature at key follow-up points (baseline, remission, and disease flare) and comparison with the IFN profiles of ICI-treated patients, regardless of whether they develop irAEs.
Phase—
TypeObservational
Age18 Years
WherePamplona, Navarre, Spain
SponsorHospital Universitario Araba
▾Tap for detailsClick for full details — eligibility, all locations, contacts Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
RecruitingThe primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary objectives of study are as follows: To estimate the PK parameters of single-ascending SC doses of HC022 in healthy subjects;To evaluate the immunogenicity of HC022 administered to healthy subjects.
PhasePhase 1
TypeInterventional
Age18 Years – 55 Years
WhereBeijing, China + 2 more
SponsorHC Biopharma Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts